Andre Moa

Recent Posts

Agile launch execution requires the right digital tools

Posted by Andre Moa on Sep 23, 2021 7:30:00 AM

The pharmaceutical industry is embracing agile ways of thinking and working in its efforts to boost productivity, creativity, speed and efficiency, all the way from laboratory to patient. That includes ensuring agile launch execution. For pharmaceutical launch activities, agility is a function not just of organisational structures or attitudinal change but of the technologies used to make those activities more visible, accessible and manageable.


Read More

Topics: launch planning, digital transformation, agile, agile launch execution

What Pfizer’s digital transformation strategy can teach us about making pharma more agile and effective

Posted by Andre Moa on Jul 22, 2021 12:02:15 PM

In the COVID-19 era, pharmaceutical companies are fast learning that digital transformation strategy is not just an appealing concept but a strategic imperative. With the pandemic offering an unexpected template for agile means of remote working, multinationals such as Pfizer have embraced digital technologies as catalysts for change at every level of their organisation.


Read More

Topics: launch planning, #covid-19, digital transformation

How COVID-19 has accelerated digital transformation in pharma

Posted by Andre Moa on Jul 1, 2021 10:52:48 AM

The COVID-19 pandemic is a wake-up call for the pharmaceutical industry to embed digital transformation at every level of its operations. That includes market access, tendering and pharma product launch activities.


Read More

Topics: launch planning, #covid-19, digital transformation

Product launches: making the most of your one shot

Posted by Andre Moa on May 19, 2021 1:12:40 PM

While some errors are unforeseen, many can be prevented with better planning, coordination, communication and transparency in launch planning and implementation. In our article for PME, we make the case for why pharma companies need a launch execution platform that makes launch excellence the norm, builds the corporate launch memory, and streamlines efforts to save time for everyone involved in product launches.


The importance of a pharma product’s launch to its success cannot be overstated. A recent analysis by Deloitte showed that most new drugs continue with the revenue trajectory set at launch – around 70 percent of products that miss expectations at launch continue doing so in subsequent years, and around 80 percent of products that meet or beat expectations continue to do so afterward.


Read More

Topics: launch excellence, launch execution, product launches

Rethinking Launch Readiness in 2021: The New Normal in the Shadow of COVID

Posted by Andre Moa on Feb 24, 2021 3:50:37 PM


It is probably reasonable enough by now to talk about the launch readiness landscape for medicines and vaccines as pre- and post-COVID. We can also say with some certainty that nothing will ever be the same again.

Read More

Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders